Morningstar

Akebia Therapeutics Inc AKBA

Morningstar Rating

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire Oct 1, 2024 8:05pm
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

PR Newswire Sep 5, 2024 12:00pm
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire Sep 3, 2024 8:16pm
Akebia Therapeutics to Present at Upcoming Investor Conferences

PR Newswire Aug 26, 2024 12:00pm
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire Aug 8, 2024 11:00am
Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

PR Newswire Aug 2, 2024 12:00pm
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire Aug 1, 2024 8:05pm
Akebia Therapeutics to Present at Upcoming Investor Conferences

PR Newswire Jul 29, 2024 12:00pm
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

PR Newswire Jul 11, 2024 10:00am
Akebia Shares Rally Premarket After FDA Approves Vafseo

Global News Select Mar 28, 2024 10:30am
Akebia: FDA Accepts Resubmission of Vadadustat Application

Global News Select Oct 25, 2023 1:00pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.